Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 1
1977 1
1979 2
1980 2
1981 8
1982 8
1983 9
1984 6
1985 16
1986 17
1987 20
1988 16
1989 14
1990 25
1991 23
1992 22
1993 21
1994 25
1995 39
1996 32
1997 39
1998 38
1999 42
2000 38
2001 50
2002 46
2003 49
2004 61
2005 44
2006 52
2007 70
2008 58
2009 88
2010 90
2011 94
2012 105
2013 99
2014 98
2015 110
2016 129
2017 126
2018 108
2019 129
2020 120
2021 119
2022 112
2023 90
2024 47

Text availability

Article attribute

Article type

Publication date

Search Results

2,280 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Limited Stage Lung Small Cell Carcinoma"
Page 1
Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review.
Petty WJ, Paz-Ares L. Petty WJ, et al. JAMA Oncol. 2023 Mar 1;9(3):419-429. doi: 10.1001/jamaoncol.2022.5631. JAMA Oncol. 2023. PMID: 36520421 Review.
IMPORTANCE: Small cell lung cancer (SCLC) is an aggressive disease that is characterized by rapid growth and the early development of metastases. ...Ongoing research has advanced the understanding of molecular categories and the immunologic microenvironment o …
IMPORTANCE: Small cell lung cancer (SCLC) is an aggressive disease that is characterized by rapid growth and the early …
Immunotherapy in Lung Cancer: Current Landscape and Future Directions.
Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI. Mamdani H, et al. Front Immunol. 2022 Feb 9;13:823618. doi: 10.3389/fimmu.2022.823618. eCollection 2022. Front Immunol. 2022. PMID: 35222404 Free PMC article. Review.
Immune checkpoint inhibitors (ICIs) have shown tremendous benefit in the treatment of non-small cell lung cancer (NSCLC) and are now being used as first-line therapies in metastatic disease, consolidation therapy following chemoradiation in unresectable local …
Immune checkpoint inhibitors (ICIs) have shown tremendous benefit in the treatment of non-small cell lung cancer (NSCLC …
Small-cell lung cancer brain metastasis: From molecular mechanisms to diagnosis and treatment.
Zhu Y, Cui Y, Zheng X, Zhao Y, Sun G. Zhu Y, et al. Biochim Biophys Acta Mol Basis Dis. 2022 Dec 1;1868(12):166557. doi: 10.1016/j.bbadis.2022.166557. Epub 2022 Sep 24. Biochim Biophys Acta Mol Basis Dis. 2022. PMID: 36162624 Free article. Review.
Lung cancer is the most malignant human cancer worldwide, also with the highest incidence rate. However, small-cell lung cancer (SCLC) accounts for 14 % of all lung cancer cases. ...
Lung cancer is the most malignant human cancer worldwide, also with the highest incidence rate. However, small-cell …
Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer.
Chen K, Yang F, Shen H, Wang C, Li X, Chervova O, Wu S, Qiu F, Peng D, Zhu X, Chuai S, Beck S, Kanu N, Carbone D, Zhang Z, Wang J. Chen K, et al. Cancer Cell. 2023 Oct 9;41(10):1749-1762.e6. doi: 10.1016/j.ccell.2023.08.010. Epub 2023 Sep 7. Cancer Cell. 2023. PMID: 37683638
PROPHET and state-of-the-art fixed-panel assays were applied to 760 plasma samples from 181 prospectively enrolled early stage non-small cell lung cancer patients. PROPHET shows higher sensitivity of 45% at baseline with circulating tumor DNA (ctDNA). …
PROPHET and state-of-the-art fixed-panel assays were applied to 760 plasma samples from 181 prospectively enrolled early stage non- …
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F; CONVERT Study Team. Faivre-Finn C, et al. Lancet Oncol. 2017 Aug;18(8):1116-1125. doi: 10.1016/S1470-2045(17)30318-2. Epub 2017 Jun 20. Lancet Oncol. 2017. PMID: 28642008 Free PMC article. Clinical Trial.
BACKGROUND: Concurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, but the optimal radiotherapy schedule and dose remains controversial. The aim of this study was to establish a standard chemoradiotherapy t …
BACKGROUND: Concurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, …
Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline.
Simone CB 2nd, Bogart JA, Cabrera AR, Daly ME, DeNunzio NJ, Detterbeck F, Faivre-Finn C, Gatschet N, Gore E, Jabbour SK, Kruser TJ, Schneider BJ, Slotman B, Turrisi A, Wu AJ, Zeng J, Rosenzweig KE. Simone CB 2nd, et al. Pract Radiat Oncol. 2020 May-Jun;10(3):158-173. doi: 10.1016/j.prro.2020.02.009. Epub 2020 Mar 23. Pract Radiat Oncol. 2020. PMID: 32222430 Free PMC article.
PURPOSE: Several sentinel phase III randomized trials have recently been published challenging traditional radiation therapy (RT) practices for small cell lung cancer (SCLC). This American Society for Radiation Oncology guideline reviews the evidence for thor …
PURPOSE: Several sentinel phase III randomized trials have recently been published challenging traditional radiation therapy (RT) practices …
Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.
Ginsberg RJ, Rubinstein LV. Ginsberg RJ, et al. Ann Thorac Surg. 1995 Sep;60(3):615-22; discussion 622-3. doi: 10.1016/0003-4975(95)00537-u. Ann Thorac Surg. 1995. PMID: 7677489 Clinical Trial.
BACKGROUND: It has been reported that limited resection (segment or wedge) is equivalent to lobectomy in the management of early stage (T1-2 N0) non-small cell lung cancer. METHODS: A prospective, multiinstitutional randomized trial was institut …
BACKGROUND: It has been reported that limited resection (segment or wedge) is equivalent to lobectomy in the management of early s …
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
Carvajal-Hausdorf D, Altan M, Velcheti V, Gettinger SN, Herbst RS, Rimm DL, Schalper KA. Carvajal-Hausdorf D, et al. J Immunother Cancer. 2019 Mar 8;7(1):65. doi: 10.1186/s40425-019-0540-1. J Immunother Cancer. 2019. PMID: 30850021 Free PMC article.
BACKGROUND: Small cell lung cancer (SCLC) accounts for 10-15% of all lung malignancies and its prognosis is dismal. ...The levels of CD3+, CD8+ and CD20+ TILs and the ratio of total/effector T-cells were significantly lower in SCLC than in non- …
BACKGROUND: Small cell lung cancer (SCLC) accounts for 10-15% of all lung malignancies and its prognosis …
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial.
Grønberg BH, Killingberg KT, Fløtten Ø, Brustugun OT, Hornslien K, Madebo T, Langer SW, Schytte T, Nyman J, Risum S, Tsakonas G, Engleson J, Halvorsen TO. Grønberg BH, et al. Lancet Oncol. 2021 Mar;22(3):321-331. doi: 10.1016/S1470-2045(20)30742-7. Lancet Oncol. 2021. PMID: 33662285 Clinical Trial.
BACKGROUND: Concurrent chemoradiotherapy is standard treatment for limited stage small-cell lung cancer (SCLC). Twice-daily thoracic radiotherapy of 45 Gy in 30 fractions is considered to be the most effective schedule. ...Participants were rand …
BACKGROUND: Concurrent chemoradiotherapy is standard treatment for limited stage small-cell lung cancer ( …
Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
Senan S, Okamoto I, Lee GW, Chen Y, Niho S, Mak G, Yao W, Shire N, Jiang H, Cho BC. Senan S, et al. Clin Lung Cancer. 2020 Mar;21(2):e84-e88. doi: 10.1016/j.cllc.2019.12.006. Epub 2019 Dec 28. Clin Lung Cancer. 2020. PMID: 31948903 Free article. Clinical Trial.
Limited-stage (LS) small-cell lung cancer (SCLC) remains an area of high unmet medical need. ...However, most patients will relapse. Durvalumab (antiprogrammed cell death ligand-1) has enhanced the efficacy outcomes after cCRT for patient …
Limited-stage (LS) small-cell lung cancer (SCLC) remains an area of high unmet medical need. ...However, …
2,280 results